Abstract: T-cell therapy involves the ex vivo isolation and expansion of antigen-specific T cells for adoptive transfer. The use of T-cell clones represents one embodiment of this approach and provides a uniform population of effector cells, so that parameters contributing to an effective response can be rigorously evaluated. T cells of defined specificity, phenotype, and function are isolated and expanded; when infused into patients, these intrinsic factors can be considered in light of extrinsic factors such as the type of conditioning regimen, cytokine support, and immunomodulatory reagents. In this chapter, 2 topics related to the use of antigen-specific T-cell clones are discussed: first, advances enabling the isolation and expansion of antigen-specific T-cell clones for human trials of adoptive therapy, and second, a contextual framework of advantages and limitations in which the use of adoptively transferred T-cell clones can be judiciously applied as a means to dissect the requirements for effective therapy.
Target Antigen
Since the first T-cell-defined tumor-associated antigen was identified in 1991, several other antigens in melanoma and other solid tumors have been discovered using T cells to screen tumor cDNA libraries, overlapping peptides sequences, or putative epitopes based on prediction algorithms. For melanoma, the predominant antigens targeted have been antigens associated with melanocyte differentiation such as MART-1 or MelanA, gp100, and tyrosinase. Although the endogenous T-cell repertoire against nonmutated self-proteins is generally characterized as low frequency, low affinity responses due to thymic selection, relatively robust antigen-specific T cells can be generated in vitro and occasionally in vivo. Superagonist-altered peptide ligands for some of these tumorassociated normal self-proteins have also been identified, which can elicit an enhanced heteroclitic response to the wild-type epitope.
An expanding family of cancer-testis or CT antigens characterized by expression in several tumors types (melanoma, breast cancer, GI cancer, lung cancer, etc) and by restricted expression in germinal tissues such as testes, fetal ovary, and placenta have become attractive targets for T-cell-based therapies for the reasons that these antigens can be highly immunogenic, broadly expressed in several cancer types and limited in its expression in normal tissues. These CT family members include the MAGE antigens (of which MAGE-A1 was the first T-cell-defined tumor antigen in humans), NY-ESO-1, GAGE, BAGE, SSX-1, PRAME, and others. Studies show that their expression is regulated by methylation, elevated in metastatic sites, and associated with early tumor progenitors.
Targeting tumor antigens directly linked to tumorigenesis, cell survival, or proliferation leads to a decreased likelihood of antigen-loss variants developing as a result of antigen-specific therapy. Such antigens include antiapoptotic genes such as survivin, and telomerase, and mutated genes responsible for cell cycling (the cyclin-dependent kinase), delivery of mitogenic signals (B-RAF), and apoptosis . In contrast to the mutation-associated antigens which are not commonly expressed in tumors, survivin and telomerase are recognized as "universal" antigens more widely expressed among several tumor types.
Peptide epitopes have been identified for these tumor antigens in the context of both class I and class II MHC. Class I MHCrestricted peptides, in particular those presented by HLA-A2, an allele expressed in 40% or more of individuals, can be synthesized as clinical grade reagents for generating antigen-specific CD8 ϩ T cells ex vivo. More recently, class II MHC-restricted peptide has been identified for several differentiation and cancer-testis antigens. These peptides can not only be used for eliciting responses but also to track infused antigen-specific T cells when incorporated into fluorochrome-conjugated peptide MHC multimers.
Enrichment and Isolation of T-Cell Clones
The process of enriching and isolating antigen-specific T-cell clones is an in vitro approximation of in vivo events and recapitulates the interaction of T cells with a TCR ligand presented on an stimulator cell in the presence of immunomodulatory cytokines. An effector population (source of T cells) can be obtained from tumorinfiltrating samples (tumor-infiltrating lymphocytes [TILs]) or peripheral blood mononuclear cells collected by phlebotomy or, in cases where larger numbers are required (Ͼ10 10 ), by leukapheresis. In the case of TIL-derived effectors, enrichment and expansion of tumor-reactive T cells are driven by high doses of IL-2 (6000 U/mL) in the presence of in situ tumor and antigen-presenting cells (APCs).
In the case of peripherally derived T cells, a greater degree of in vitro manipulation is required. Stimulator cells (ie, autologous dendritic cells, monocytes, or activated B cells) may be obtained from the same peripheral blood mononuclear cell source as the T cells and pulsed with the immunogenic epitope peptide of interest or engineered to express, using recombinant viral vectors, the tumor target antigen. In most cases, monocyte-derived dendritic cells are generated after a 7-day treatment with GM-CSF and IL-4, followed by exposure to a maturation cocktail to upregulate expression of costimulatory receptors. When charged with the epitope peptide or transfected with RNA or recombinant vector expressing the target of interest PMID: 18338820; PMID: 1875170, (??) these APCs are then cocultivated with autologous responder T cells. Exposure to specific cytokines can modulate the magnitude (IL-7, IL-15, and IL-2) and phenotype (IL-21 and IL-10) of T cells that are generated after iterative cycles of restimulation (see later). Generally, 2 to 3 cycles are sufficient to enrich for a population of antigen-specific T cells from which clones can be isolated by limiting dilution culture.
Alternatively, artificial APCs (aAPCs) can be used in place of autologous APCs. aAPCs are more readily available, more likely to be uniform in their physical and functional properties, and permit greater flexibility in expressing desired antigen-specific or costimulatory receptors. Cellular aAPCs can be generated using mouse fibroblast lines, insect cells, and the human NK cell line, K562, by engineering expression of the relevant HLA allele together with costimulatory receptors B7.1, ICAM-1, LFA-3, and/or 4-1BBL. Acellular aAPCs, such as magnetic beads, liposomes, and exosomes, can be decorated with requisite receptors to augment T-cell expansion in vitro.
Once an antigen-specific T-cell-enriched population is established, "brute-force cloning" by limiting dilution cultures may require that several hundred cultures be screened to identify clones with antigen-specific reactivity. Clonal selection may be more efficiently accomplished using reagents that can nondestructively identify antigen-specific T cells, for example, using peptide-MHC multimers. As a monomer, the natural ligand for the TCR, the peptide-MHC complex, dissociates too quickly to be of use as a staining reagent for antigen-specific T cells. By multimerizing pMHC complex to a fluorophore-conjugated avidin molecule in a method first pioneered by the Davis laboratory, the pMHC multimers can then be used to stain for antigen-specific T cells in a nondestructive manner, thus allowing such T cells not only to be tracked but also to be isolated for downstream analysis or clonal selection and expansion for adoptive therapy. 1,2 Ig fragments to multimerize pMHC complexes for ex vivo detection, [3] [4] [5] (as well as in vivo stimulation); class II tetramers have also been generated to allow for identification and selection of somewhat more elusive antigen-specific CD4 T cells. 5, 6 Without prior knowledge of the peptide and its restricting MHC, selection of antigen-specific T cells may also be achieved by exploiting functional antigen-driven properties such as cytokine production or surface marker upregulation. 7, 8 
Expansion of Antigen-Specific T-Cell Clones
The method of expanding T cells using high doses of IL-2 can yield a 20-to 100-fold increase in cell numbers over several weeks; however, without a TCR ligand and other accessory factors, these T cells are relatively short lived. In 1990, a method was developed by Riddell and Greenberg using a TCR ligand (anti-CD3), a high ratio of irradiated feeder Pumps (??) and LCLs to effector T-cell clones and repeat dosing of moderate dose IL-2 (50 U/mL) in a 14-day iterative stimulation cycle. When stimulated in this fashion, antigenspecific T cells became highly activated within the first few days, upregulating high-affinity IL-2 receptor and other activation molecules and becoming "blast"-like in appearance; during the course of 14-days, these T cells reverted back to small resting cells, recycling TCR back onto the surface in a fashion reminiscent of its natural in vivo response. The accessibility of clinical reagents OKT3 (the TCR ligand), Aldesleukin (IL-2, at 40 -80-fold lower doses than that used for melanoma therapy), and irradiated feeder peripheral blood mononuclear cells and LCLs enabled its translation to clinical studies. This strategy, also known as a Rapid Expansion Protocol ("REP") can be used to expand antigen-specific CD8 and CD4 T-cell clones from 1000 to Ͼ5000-fold through 1 14-day cycle.
An alternative approach adheres to similar principles but uses plate-or bead-bound anti-CD3 and anti-CD28 in place of the TCR ligand and feeder cell population. Although coating plates with these ligands can be effective in expanding tumor-reactive T cells, 9 this approach is most effective when bound to paramagnetic beads where expansion of T cells in peripheral blood to Ͼ1000-fold can routinely be achieved. Donor lymphocytes activated with anti-CD3 and anti-CD28-coated beads have been used to treat leukemic relapse after allogeneic stem-cell transplant and enhance engraftment and lymphocyte recovery of patients with non-Hodgkin Lymphoma, 10 whereas in the autologous setting, patients with myeloma and RCC have received aCD3/CD28-activated lymphocytes with promising results. 10, 11 Expansion of T-cell clones using aCD3/CD28 beads achieves levels of expansion sufficient for adoptive therapy and seems to facilitate maintenance of CD28 expression in T-cell clones (unpublished data) that may translate to improved in vivo survival.
T-CELL CLONES FOR ADOPTIVE THERAPY: PRO ET CONTRA
The use of a clonal population of effector cells with uniform specificity and phenotype can be a highly informative approach for addressing specific questions in the field of T-cell-based immunotherapy, but the possible advantages and limitations in its use should be considered in the context of its application and purpose. In this section, the potential drawbacks to using T-cell clones for adoptive therapy are addressed along with its unique advantages over the use of a polyclonal T-cell or TIL population.
Contra: Potential Limitations
Among the possible concerns related to the use of T-cell clones for adoptive therapy is the development of antigen-loss tumor variants when targeting a single epitope and the replicative senescence of T-cell clones after in vitro expansion.
Antigen-Specific Therapy and Antigen-Loss Tumor Variants
A highly focused T-cell response against a specific epitope or tumor antigen may increase the likelihood of antigen-loss tumor variants arising after T-cell-based therapy. This mechanism of immune escape has been observed in both monospecific vaccine and adoptive therapy. However, complete tumor regression has also been documented after epitope-specific therapy targeting MAGE-A3, MART-1/MelanA, or NY-ESO-1 and has been attributed to the in vivo induction of endogenous T-cell responses to nontargeted tumor-associated antigens in a phenomenon known as "epitope-," "intermolecular," or "antigen-spreading." [12] [13] [14] [15] This has been observed with adoptive therapy using CD8 12, 14 and CD4 T-cell clones. 13 In the latter, patients receiving CD4 T-cell clones targeting only the DP4-restricted epitope of the cancer-testis antigen NY-ESO-1 yielded endogenous T-cell responses to nontargeted antigens (eg, MAGE-A3 and MART-1) after adoptive transfer 13 (and unpublished data). Perhaps, the proinflammatory milieu established by CD4 T-cell-derived cytokines and APC-activating signals (eg, by CD40) delivered by the antigen-specific CD4 T cells engendered a cellular response against multiple target antigens. On the basis of this and other studies that, although a T-cell response targeting multiple epitopes/antigens can mitigate against the development of antigen-negative tumor, it may not be an absolute requirement. In fact, the dramatic clinical responses observed in patients receiving nonmyeloablative conditioning and infusion of REP-expanded TILs (more than 50% of patients with advanced diseases responding with several complete responders among them) were often accompanied by in vivo expansion of a clonal population of T cells that was sufficient to mediate complete tumor regression. 16, 17 Consideration should also be given to the antigen target itself. In cases where T-cell clones target a protein associated with tumorigenesis or tumor cell "stemness," complete tumor eradication may be achieved in cancers because antigen-loss variants are less likely
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In Vivo Persistence of In Vitro Expanded T-Cell Clones
An important consideration when using T-cell clones has been the concern that the iterative expansion of a single T-cell clone to the billions used for adoptive therapy can lead to a shortened cellular lifespan. Attempts to extend the survival of T cells by engineering telomerase expression in T-cell clones have produced mixed results. 18, 19 After REP expansion, TIL cells display shorter telomeres on average 20 and telomere length has been associated with engraftment and long-term in vivo survival of adoptively transferred T cells. 21, 22 In early studies of adoptive therapy conducted by the Surgery Branch at the NCI, gp100-specific CD8 T-cell clones established in culture with high-dose IL-2 from the peripheral blood of patients with metastatic melanoma previously vaccinated with the superagonist peptide of gp100 (G209M), experienced Ͻ24 hours of in vivo persistence, even when measured by the most sensitive method of RT-PCR for the unique, clone-specific CDR3 region. When nonmyeloablative conditioning with high-dose cytoxan and fludarabine were added, these transferred T-cell clones still failed to persist. The results of these studies stand in contrast to reports from at least 2 other groups using antigen-specific T-cell clones, where, in these latter cases, in vivo persistence, trafficking to tumor sites and evidence of clinical responses were observed. 12, 14, 23, 24 These responses were often characterized as disease stabilization or partial responses, and for most patients, who presented with progressive refractory disease, this represented a favorable clinical outcome. When patients were conditioned with fludarabine alone, a 3-fold increase in the duration of in vivo persistence of transferred T-cell clones, in some cases, to more than 4 weeks was observed. 24 Unpublished data presented recently from a trial of 6 patients using high-dose cyclophosphamide conditioning produced objective clinical responses, including a durable complete response, in patients receiving CD8 T-cell clones targeting melanocyte differentiation antigens. T-cell persistence was observed for more than 2 months at frequencies of Ͼ1% in responding patients. One reason for the observed differences between these latter studies and the NCI results pertaining to T-cell survival and clinical responses (which have been shown to be linked to in vivo persistence 25 ) may be the manner in which the antigen-specific T-cell clones were generated. An antigenspecific T-cell population driven to proliferate in vivo by repeated vaccination that is then collected from patients failing therapy and exposed in vitro to high-dose IL-2 to further expand (as described in the NCI studies) 26, 27 are more likely to exhibit a terminally differentiated phenotype than those T-cell clones isolated from the repertoire of previously nonvaccinated patients, enriched in vitro with cyclic antigen stimulation and low-dose IL-2 and then expanded for adoptive transfer in patients who have not failed prior antigenspecific therapy. 12, 14, 23, 24 T-cell clones generated by this latter approach have been shown to retain the ability to rapidly proliferate when exposed to low-dose IL-15 and or IL-2 after in vitro REM expansion and may be 1 reason for their enhanced survival in the lymphodepleted host.
That T-cell clones expanded to several billion from a single cell continue to exhibit high-replicative capacity may not be surprising. 12, 14, 28 It has been estimated that the lifespan of T cells measured in population doublings can range from 35 to 80 population doublings, with more differentiated memory cells approaching the low end and naive and early/central memory effectors occupying the upper end of this range. 29 A single cell undergoing REP expansion to 10 10 cells/m 2 , the current standard dose and upper limit tested for T-cell clones, requires 34 doublings. Given the upper limit of 80 doublings, the potential for at least 10 doublings after adoptive transfer at this point would be feasible; this represents a 1000-fold expansion, ie, more than 10 13 lymphocytes, which is equivalent to the total number of lymphocytes in the human body. Although this is mathematically tenable, the caveat is that T-cell clones be screened for their replicative potential before selection for in vitro expansion. To this end, developing strategies that favor the generation of early effector T-cell clones would be desirable. Recently, it has been shown in a nonhuman primate model that CTL derived from a central memory population are able to persist long-term in vivo after adoptive transfer and revert to the memory cell pool. 30 In murine studies, the use of early effectors translates to enhanced in vivo antitumor efficacy and persistence. 31 In preclinical studies, human CD8 ϩ T cells exposed to the gamma-chain receptor cytokine, IL-21, during primary in vitro stimulation yield a population of CD28 hi central memory-like clones with high replicative potential and may represent T cells that expanded but are differentiation arrested and, therefore, may be more effective in vivo. 32 Alternatively, strategies may be applied to engineer longevity into T cells by forced expression of CD28, antiapoptotic factors, and chimeric cytokine receptors (Fig. 1) . [33] [34] [35] [36] 
Pro: Potential Advantages

Uniform Antigen Specificity and Affinity
The earliest evidence that T cells can reject established tumor was discovered more than 30 years ago in patients receiving allogeneic stem-cell transplant who developed graft-versus-host disease (GVHD). 37 Recipients of T-cell-depleted marrow experienced the highest frequency of relapse, whereas those who developed GVHD experienced a greater probability of disease-free survival. Efforts to separate the graft-versus-leukemia from the GVH effect were made by several groups who successfully identified recipient tissue-specific minor antigens that could theoretically be targeted without inducing GVHD. Minor antigens are derived from polymorphic genes that differ between the donor and recipient tissues and can elicit CD8 ϩ and CD4 ϩ T-cell responses. Selective targeting of mHAg expressed only on recipient normal, and malignant hematopoietic cells can mediate an antileukemic effect without triggering or exacerbating GVHD. Since 1995, more than 30 different mHAgs have been discovered 38, 39 ; among these, several are preferentially or uniquely expressed in hematopoietic tissues and represent good candidates for inducing a beneficial graft-versus-leukemia effect.
The first-in-human use of donor-derived T-cell clones targeting tissue-restricted minor antigens for the treatment of patients with relapsing leukemia after allogeneic HSCT was recently completed with promising results in 5 of 7 patients with recurrent leukemia who achieved a complete but transient response. 40 In this example, the use of a uniform population of T-cell clones with well-defined specificity was critical to minimizing toxicity. However, serious pulmonary toxicity was observed in 1 patient due to unanticipated expression of the minor antigen target in lung epithelium. The observation that tumor-associated antigens may be shared among normal tissues represents an increasingly important paradigm in immune-based therapies, especially when such target antigens are nonmutated products. In the case of patients with melanoma, adoptive transfer of T cells targeting the melanocyte differentiation antigens is often accompanied by a skin rash and vitiligo, 12,41 but other unforeseen autoimmune toxicities have been observed in tissues that were later discovered to express differentiation antigens, such as the inner ear. 42 In retrospect, the discovery that minor antigen or differentiation antigen targets were expressed on lung or inner ear tissues would not have been possible unless an effector population with uniform specificity revealed these "ontarget" effects. Because it would be possible to screen for T-cell clones with some precision on the basis of their affinity for the The Cancer Journal • Volume 16, Number 4, July/August 2010 Adoptive Therapy target antigen, it may be desirable to select and expand a population of T-cell clones with uniform high tumor avidity for adoptive transfer; alternatively, when targeting a self-antigen, consideration can be given to avoid on-target autoimmune toxicities by selecting a T-cell clone with an attenuated response, so as to allow more specific recognition of tumors overexpressing the target antigen of interest.
Uniform Phenotype
The use of a population of T-cell clones that is phenotypically uniform on the basis of CD8 or CD4 expression, specific CD4 Th subset, cytokine/chemokine profile, or stage of differentiation may instruct the design of future studies in adoptive therapy and vaccine strategies.
CD4 T Cells.
Historically, CD8 T-cell clones were more commonly, and almost exclusively, developed for clinical trials because class I-restricted epitopes were identified early on for several tumorassociated antigens. Clinical grade peptides corresponding to these epitopes could be readily obtained for in vitro stimulation and expansion of CD8 T cells for adoptive therapy. More recently, class II-restricted epitopes derived from several tumor-associated antigens including melanoma differentiation antigens and several, more broadly expressed, cancer-testis antigens have been identified. When class II-restricted epitopes were sequenced, it became feasible to generate antigen-specific CD4 T cells, which in murine and preclinical studies were postulated as being critical for an effective immune response for several reasons including its capacity to impart antigendriven autocrine/paracrine signals to enhance survival and provide helper function to CTL, [43] [44] [45] license APCs, and recruit effectors that favor a broadened and more robust endogenous response and mediate a direct antitumor effect through alternative mechanisms. 46 -49 To evaluate their safety, persistence, and efficacy, CD4 T-cell clones targeting tyrosinase or NY-ESO-1 (in patients whose tumor expressed the relevant target protein) were used for adoptive therapy for patients with metastatic melanoma in an early-phase dose escalation study. In the absence of any lymphodepletion conditioning or exogenous cytokines, adoptively transferred CD4 T-cell clones persisted in vivo for more than 30 days among 5 of the 9 patients treated, and patients receiving higher doses experienced partial responses, disease stabilization of refractory progressive metastatic melanoma, and in 1 case, a complete durable response. The emergence of endogenous T-cell responses to nontargeted tumor-associated antigens, also known as "antigen-spreading" was observed in several patients 13 (and unpublished data) and may have contributed to tumor regression and in those evaluable, the absence of the outgrowth of antigen-loss tumor variants.
Cytokine/Chemokine Profile. In infectious diseases such as vaccinia and HIV, a polyfunctional T-cell response correlates with immuno- . Among the TIL population are tumor cells, antigen-presenting cells, and a population of tumor-reactive infiltrating lymphocytes, which can be expanded in vitro after exposure to high-dose IL-2. PBMC provide a source of antigen-presenting cells such as autologous dendritic cells or CD40-activated B cells that can be pulsed with peptide or engineered by genetic approaches to express the target antigen of interest T cells may be selected from the PBMC or used as unmanipulated responders and added to stimulator APCs in vitro. Donor LCLs are used when generating minor antigen-specific T cells in the setting of an allogeneic hematopoietic stem-cell transplant recipient. In some cases, artificial APCs are used in place of autologous APCs or donor LCLs. Artifical APCs can be represented by modified paramagnetic beads, insect cells, or MHC-negative NK cell lines (K562) that have been decorated with the relevant HLA allele and costimulatory molecules to enhance antigen-specific T-cell activation. T cells and APCs are cocultivated with modulatory cytokines, usually, gamma-chain receptor cytokines such as IL-2, IL-7, IL-15, and/or IL-21 to facilitate in vitro propagation. Enriched cultures are cloned by limiting dilution in microwells or selected in vitro using peptide-MHC multimer reagents or other strategies based on activation-driven functional markers. T-cell clones may be expanded to large numbers using a rapid-expansion method (REM) described in text before their use in adoptive therapy.
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The Cancer Journal • Volume 16, Number 4, July/August 2010 protection 50 -53 for both CD4 and CD8 T cells. Murine and preclinical studies suggest that antitumor responses may also be modulated by a local polyfunctional response, 54, 55 and among patients receiving anti-CTLA4, polyfunctional NY-ESO-1-specific T-cell responses were only observed in clinical responders. 56 Antigen-specific CD4 T-cell clones with distinct and stable cytokine/chemokine profiles can be isolated from patients with metastatic melanoma (unpublished data, Yee et al). By selecting for adoptive therapy, a T-cell clone with a defined chemokine/cytokine profile, it may be possible to identify a polyfunctional phenotype that yields a favorable immunologic response and yields clinical benefit. For example, a T-cell clone that secretes high levels of IL-2 and IFN-gamma but low or negligible levels of IL-10 or T H 2-type cytokines may be a desirable effector. As murine studies have shown, the use of IL-17-producing CD4 T cells has, in some cases, demonstrated a superior antitumor response (although the plasticity of such T cells may confound straightforward selection). [57] [58] [59] [60] Finally, the selection of an effector clone with a chemokine profile that attracts innate effectors and other antigen-specific T cells to the tumor site could prove to be clinically beneficial.
Differentiation State. One insight borne out of the clinical studies using TIL cells performed by the NCI and studies of adoptive cellular therapy using T-cell clones is that the in vivo clinical response is related to in vivo persistence and that methods to modulate and/or identify tumor-reactive T cells with enhanced replicative potential would lead to more effective therapy. 14, 16, 25, [61] [62] [63] [64] Indeed, data from murine models demonstrate the superior antitumor effect of "early effector" T cells, 65 and in nonhuman primates, it was recently demonstrated that methods to enrich for T cells exhibiting central memory programming are more likely to experience an extended period of in vivo persistence even when driven along an effector pathway. 30 Preclinical studies in human T cells suggest that arrested differentiation after exposure to IL-21 can lead to the enrichment of a population of effectors with high replicative potential. 66, 67 Under appropriate conditions, isolating and expanding a T-cell clone with enhanced proliferative capacity on the basis of the in vitro manipulations described earlier would provide a uniform population of effector cells with a high intrinsic capacity for long-term in vivo persistence.
Tracking Effector Cells. Genetically marking effector T cells in vitro before adoptive transfer represents 1 approach to tagging infused cells, so that they can be tracked in vivo and their identity confirmed in patient samples. Early attempts at using gene-marked T cells were hindered by the low transduction efficiency of recombinant vectors and gene expression in resting or activated T lymphocytes, 68 and by the immunogenicity of the nonhost marker proteins, which led to premature elimination by the endogenous immune response. 69 More recently, the use of newly developed vectors and nonimmunogenic markers addressed both concerns and provided an efficient means of tracking infused T cells. 70 -72 Genetically marking antigen-specific T-cell clones would afford an opportunity to unequivocally evaluate the long-term fate of infused T cells of a defined specificity and phenotype (see earlier) that could not be easily achieved by other means. However, although this technology is feasible, its implementation for clinical trials still faces regulatory and technical challenges. In the absence of using genemarked cells, the use of T-cell clones still retains an appeal for the ability to track these T cells in vivo because they provide a means to confirm their identity in patient samples by sequencing the clonespecific hypervariable CDR3 region of the T-cell receptor and comparing this sequence with the infused clone. For example, T cells sorted on the basis of antigen-specific binding to peptide-MHC multimer complexes can be identified as the infused clone on the basis of their CDR3 sequence. In cases where peptide-MHC multimers are not available, the frequency of the infused clone may be determined using quantitative PCR assays, which have been optimized for the clone-specific CDR3 sequence. 13, 14, 25 Although some class II and several class I peptide-MHC multimers can be generated, 1,2,5,73 their use is generally limited to more common HLA-A2 epitopes.
For those cases where labeled pMHC tetramers can be used, multiparametric analysis can be applied to evaluate functional and surface phenotype of transferred T cells. 74, 75 In clinical trials of adoptive therapy using TILs, long-term persistence was accompanied in responding patients by a transition in T-cell phenotype from CD27 lo /28 lo to CD27ϩ/28ϩ in vivo. 20 Without the use of genemarked cells or antigen-specific T-cell clones, it would not be possible to conclude whether these T cells arose from a small subpopulation of CD27ϩ/28ϩ cells that were already present in the infusate or that this transition/reversion to a central memory phenotype occurred in the infused clone, akin to observations made in preclinical studies. 30, 76 In clinical trials, this in vivo transition from a CD27 lo /28 lo to CD27ϩ/28ϩ phenotype has been observed in an adoptively transferred highly persistent T-cell clone in vivo 77 (unpublished data).
Evaluation of Extrinsic Factors in Adoptive Therapy. In general, extrinsic factors influencing the fate or behavior of transferred T cells in vivo are those, arbitrarily defined, as factors not associated with inherent properties of the T-cell clone but rather the external milieu such as host conditioning, exogenous cytokines, immunomodulatory reagents, and vaccines. Because T-cell clones provide a highly uniform population of effector cells that can be tracked after infusion, interpatient variability may be attenuated using T-cell clones with similar intrinsic properties (target affinity, specificity, differentiation phenotype, etc) allowing more meaningful interpretation of results when evaluating, for example, a given conditioning regimen 12, 24 or the influence of an immune checkpoint inhibitor (eg, anti-CTLA4). In some cases, a study can incorporate an intrapatient design using the identical autologous T-cell clone for an initial baseline infusion and then after a washout period, the same T-cell clone for the experimental condition, thus allowing for a statistically more powerful comparison. In the case where fludarabine conditioning was being evaluated, 24 it was clear that, despite wide variability in the persistence of individual clones among patients, when intrapatient comparisons were made of the in vivo persistence of the T-cell clone given first without, and then, subsequently, the same T-cell clone given with prior fludarabine conditioning, the addition of fludarabine conditioning led to enhanced T-cell survival, which was highly statistically significant.
In the case where the benefits of a combined biologic approach using an immune checkpoint inhibitor, such as anti-CTLA4 together with adoptive cellular therapy are being examined, the use of antigen-specific T-cell clones affords the opportunity to evaluate more rigorously whether coadministration of anti-CTLA4 enhances not only the activity of adoptively transferred T cells but also, by lowering the threshold for effector T-cell activation, promotes the generation of T-cell responses against a broader panel of tumorassociated antigens that are released in a proinflammatory environment after CTL-mediated tumor lysis. 78, 79 Because the CTL target is well defined, endogenous nontargeted responses resulting from this combined approach can be more precisely evaluated when using clones rather than polyclonal effectors.
FUTURE OF T-CELL CLONES IN ADOPTIVE T-CELL THERAPY
As more and more biologic reagents are being developed for clinical use, 56,80 -83 and conventional modalities are being evaluated
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Adoptive Therapy for their immunomodulatory activity, 84 -86 the use of an effector population such as antigen-specific T-cell clones with defined intrinsic properties will allow investigators the opportunity to exercise rigorous control over 1 variable, while evaluating the influence of others. The isolation and expansion of tumor-associated antigenspecific T cells can be a time and labor-intensive process; however, several novel in vitro strategies to expedite the generation and selection of effectors of a desired phenotype and function are now being advanced into the clinical arena. 2, 76, [87] [88] [89] [90] [91] [92] The use of T-cell clones for adoptive therapy is unlikely to address all issues confronting the field, but when used judiciously in the proper context, it may not only prove to be clinically beneficial but also uniquely suited to instructing the design of future studies in antigen-specific T-cell-based immunotherapy.
